Hooker Furnishings Corporation - Common Stock (HOFT)
12.73
-0.41 (-3.12%)
Hooker Furnishings Corporation is a leading designer, manufacturer, and importer of a wide range of home furnishings, including upholstered furniture, case goods, and decorative accessories
The company is known for its diverse product lines that appeal to various market segments, including residential and contract markets. With a focus on quality craftsmanship and innovative design, Hooker Furnishings collaborates with retailers, interior designers, and architects to deliver stylish and functional products that enhance living spaces. The company also prioritizes sustainability and environmentally friendly practices in its operations, contributing to the creation of beautiful homes while promoting responsible sourcing and manufacturing.
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 22-23, 2025. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Hooker Furnishings Corp. continues to focus on execution during this sustained downturn in the furniture industry. This Zacks Rank #5 (Strong Sell) is expected to see a big decrease in earnings in fiscal 2025.
The furniture business is down due to weakness in housing, but long-term indicators are favorable, and the FOMC is on track to cut rates, so a rebound is ahead.
Companies Reporting Before The Bell • Kore Group Holdings (NYSEKORE) is estimated to report quarterly loss at $0.05 per share on revenue of $77.79 million.
Hooker Furnishings Corp (NASDAQHOFT) reported a third-quarter FY24 sales decline of 22.9% year-on-year to $116.83 million, beating the analyst consensus estimate of $11
Gainers Biocept, Inc. (NASDAQBIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics.
